Free Trial

Orchestra BioMed 8/12/2024 Earnings Report

Orchestra BioMed logo
$5.17 -0.11 (-2.08%)
As of 04:00 PM Eastern

Orchestra BioMed EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.78 million
Expected Revenue
$1.04 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Orchestra BioMed Earnings Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode in 2025! Trump could trigger THIS crypto coin…
Orchestra BioMed initiated with an Overweight at Barclays
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat